Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.
Francolini G, Porreca A, Facchini G, Santini D, Bruni A, Simoni N, Trovò M, Osti MF, Fornarini G, Sisani M, Di Cataldo V, Detti B, Garlatti P, Bertini N, Serni S, Minervini A, Livi L. Francolini G, et al. Among authors: fornarini g. Med Oncol. 2023 Dec 29;41(1):39. doi: 10.1007/s12032-023-02268-3. Med Oncol. 2023. PMID: 38157111 Clinical Trial.
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
Ghiorzo P, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bernard L, Bonelli L, Borgonovo G, Bruno W, De Cian F, Decensi A, Filauro M, Faravelli F, Gozza A, Gargiulo S, Mariette F, Nasti S, Pastorino L, Queirolo P, Savarino V, Varesco L, Scarrà GB; Genoa Pancreatic Cancer Study Group. Ghiorzo P, et al. Among authors: fornarini g. J Med Genet. 2012 Mar;49(3):164-70. doi: 10.1136/jmedgenet-2011-100281. J Med Genet. 2012. PMID: 22368299
BRCA1 and BRCA2 mutations in central and southern Italian patients.
Ottini L, D'Amico C, Noviello C, Lauro S, Lalle M, Fornarini G, Colantuoni OA, Pizzi C, Cortesi E, Carlini S, Guadagni F, Bianco AR, Frati L, Contegiacomo A, Mariani-Costantini R. Ottini L, et al. Among authors: fornarini g. Breast Cancer Res. 2000;2(4):307-10. doi: 10.1186/bcr72. Epub 2000 Mar 31. Breast Cancer Res. 2000. PMID: 11056688 Free PMC article.
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
International Prognostic Factors Study Group; Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. International Prognostic Factors Study Group, et al. J Clin Oncol. 2010 Nov 20;28(33):4906-11. doi: 10.1200/JCO.2009.26.8128. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956623
Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy.
Ghiorzo P, Gargiulo S, Nasti S, Pastorino L, Battistuzzi L, Bruno W, Bonelli L, Taveggia P, Pugliese V, Borgonovo G, Mastracci L, Fornarini G, Romagnoli P, Iiritano E, Savarino V, Bianchi-Scarrà G. Ghiorzo P, et al. Among authors: fornarini g. J Clin Oncol. 2007 Nov 20;25(33):5336-7; author reply 5337-8. doi: 10.1200/JCO.2007.13.5624. J Clin Oncol. 2007. PMID: 18024887 No abstract available.
First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A. Pessino A, et al. Among authors: fornarini g. Ann Oncol. 2008 Apr;19(4):711-6. doi: 10.1093/annonc/mdm516. Epub 2007 Dec 10. Ann Oncol. 2008. PMID: 18073221 Free article. Clinical Trial.
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G. Bracarda S, et al. Among authors: fornarini g. Future Oncol. 2014 May;10(6):975-83. doi: 10.2217/fon.13.256. Epub 2013 Dec 3. Future Oncol. 2014. PMID: 24295376 Free article. Clinical Trial.
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. Iacovelli R, et al. Among authors: fornarini g. Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. Anticancer Drugs. 2018. PMID: 29846246
Enzalutamide in Castration-Resistant Prostate Cancer.
Bregni G, Rebuzzi SE, Fornarini G. Bregni G, et al. Among authors: fornarini g. N Engl J Med. 2018 Oct 4;379(14):1380-1. doi: 10.1056/NEJMc1810065. N Engl J Med. 2018. PMID: 30284801 No abstract available.
151 results